Cited 0 times in
A prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 송정식 | - |
dc.contributor.author | 안성수 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 표정윤 | - |
dc.date.accessioned | 2023-08-09T07:04:05Z | - |
dc.date.available | 2023-08-09T07:04:05Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1759-720X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196042 | - |
dc.description.abstract | Background: Studies have proposed that nutritional and immune-related markers are relevant with patient outcomes of various medical conditions and could be a useful indicator of patient prognostication. Objectives: This study investigated whether a prognostic immune nutritional index (PINI) at diagnosis could predict adverse clinical outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Design: A retrospective, single-centre observational cohort analysis of patients with AAV. Methods: All-cause mortality and end-stage renal disease (ESRD) were investigated outcomes during the observation period. PINI was calculated by serum albumin (g/mL) × 0.9 - monocyte count (/mm3) × 0.0007, and the optimal cut-off of PINI was obtained using a Youden index-based bootstrapping method. Cox hazard analyses were performed to identify independent predictors of patient outcomes. Results: Of the 250 eligible patients, the median age of patients was 60.0 years, and 34.0% were men. During the disease course, 33 (13.2%) died and 42 (16.8%) developed ESRD, respectively. The ideal PINI cut-offs for all-cause mortality and ESRD were set as ⩽2.47 and ⩽3.12 (sensitivity and specificity of 75.1% and 60.6% for mortality and 46.2% and 78.6% for ESRD). AAV patients with PINI ⩽2.47 and those with PINI ⩽3.12 exhibited significantly higher rates for all-cause mortality and ESRD compared to those with PINI >2.47 and >3.12. In the multivariable Cox analysis, PINI ⩽2.47 (hazard ratio [HR]: 3.173, 95% confidence interval [CI]: 1.129, 8.916, p = 0.029) was independently associated with all-cause patient mortality; however, PINI ⩽3.12 was not independently associated with ESRD (HR: 1.097, 95% CI: 0.419, 2.870, p = 0.850). Conclusion: Findings from this study demonstrated PINI could predict all-cause patient mortality in AAV, and a higher clinical attention is warranted in those with PINI ⩽2.47 at initial diagnosis. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Sage Publications | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | A prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sung Soo Ahn | - |
dc.contributor.googleauthor | Jung Yoon Pyo | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.identifier.doi | 10.1177/1759720X231188818 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02233 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A04244 | - |
dc.relation.journalcode | J03811 | - |
dc.identifier.eissn | 1759-7218 | - |
dc.identifier.pmid | 37529333 | - |
dc.subject.keyword | antineutrophil cytoplasmic antibody | - |
dc.subject.keyword | end-stage renal disease | - |
dc.subject.keyword | mortality | - |
dc.subject.keyword | prognostic immune nutritional index | - |
dc.subject.keyword | vasculitis | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.contributor.affiliatedAuthor | 송정식 | - |
dc.contributor.affiliatedAuthor | 안성수 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.contributor.affiliatedAuthor | 표정윤 | - |
dc.citation.volume | 15 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 12 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, Vol.15 : 1-12, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.